Aldeyra refocuses pipeline on next-gen RASP modulators despite positive phase II success

ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia

FDA grants breakthrough status to Augurex’s SPINEstat test to advance early axSpA diagnosis

AbbVie’s RINVOQ shows promise in Vitiligo Phase 3 trials

Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body

GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy

The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio

Lilly’s Omvoh shows rapid and lasting relief from bowel urgency in ulcerative colitis patients

EU approves Alexion’s Koselugo to treat adults with neurofibromatosis type 1 tumours

Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1

MedCognetics and Laurel Bridge unite to revolutionize breast cancer screening with secure AI workflow

Lupin Digital Health launches VITALYFE

AI-powered cardiometabolic wellness platform for India’s workforce

Roche’s Gazyva shows strong phase III results for treatment of idiopathic nephrotic syndrome

Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva

Lilly and NVIDIA join forces to build world’s most powerful AI supercomputer for drug discovery

New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents